Catalytic antibodies in patients with systemic lupus erythematosus
Antibodies with catalytic (hydrolytic) properties to DNA or RNA have been reported in systemic lupus erythematosus (SLE). However, it is well known that ethnicity plays an important role in the presentation of SLE and severity of the disease; hence, these data may not truly represent a general featu...
Gespeichert in:
Veröffentlicht in: | European journal of rheumatology 2018-09, Vol.5 (3), p.173-178 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 178 |
---|---|
container_issue | 3 |
container_start_page | 173 |
container_title | European journal of rheumatology |
container_volume | 5 |
creator | Pradhan, Vandana Pandit, Pallavi Surve, Prathamesh Lecerf, Maxime Rajadhyaksha, Anjali Nadkar, Milind Khadilkar, Prasad V Chougule, Durga A Naigaonkar, Aalaap A Lacroix-Desmazes, Sébastien Bayry, Jagadeesh Ghosh, Kanjaksha Kaveri, Srini V |
description | Antibodies with catalytic (hydrolytic) properties to DNA or RNA have been reported in systemic lupus erythematosus (SLE). However, it is well known that ethnicity plays an important role in the presentation of SLE and severity of the disease; hence, these data may not truly represent a general feature of all SLE patients. Therefore, we have analyzed the hydrolyzing activity of immunoglobulin G (IgG) of SLE patients from the Indian population with an aim to decode whether the catalytic antibody response represents part of an active disease process.
IgGs were isolated from the sera of 72 consecutive patients diagnosed with SLE. As a control, IgGs from healthy donors were used. The catalytic activity of IgG was measured by PFR-MCA and affinity-linked oligonucleotide nuclease assay.
IgGs from patients with SLE from the Indian subcontinent displayed significantly higher hydrolysis rates of both the surrogate substrate, PFR-MCA, and the DNA than IgG from healthy individuals. Intergroup comparisons of the IgG-PFR-MCA interactions with clinical manifestations of the disease demonstrated a significantly increased level of hydrolysis among the patients with renal involvement who tested positive for anti-dsDNA antibodies. The PFR-MCA hydrolysis also appears to be associated with the active disease (p=0.0988, vs. inactive group).
The prevalence of catalytic antibodies represents a general feature of SLE patients, irrespective of their origin. |
doi_str_mv | 10.5152/eurjrheum.2018.17194 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6116854</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A559690637</galeid><sourcerecordid>A559690637</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-2cc608bee6a2c818c4141dbad2d8c7891b7da6c7a5fe924a645686b3660a8dde3</originalsourceid><addsrcrecordid>eNptUl1rFDEUDaLYsvYfiAz4og-zzdfk40VYF7XCQl_qc8gkdzop87FOMi37781062Kl5CHh3nPOvZwchN4TvK5IRS9hnu6mFuZ-TTFRayKJ5q_QOSVclZxK_frxLUstKT5DFzHeYYyJpFQT-RadsUyqmMTn6OvWJtsdUnCFHVKoRx8gFmEo9jYFGFIsHkJqi3iICfoM6ub9HAuYDqmF3qYxzvEdetPYLsLF071Cv75_u9lelbvrHz-3m13pmGappM4JrGoAYalTRDlOOPG19dQrJ5UmtfRWOGmrBjTlVvBKKFEzIbBV3gNboS9H3f1c9-Bd3m6yndlPobfTwYw2mOedIbTmdrw3ghChKp4FPh8F2v9oV5udWWqYMqoo5fckYz89DZvG3zPEZPoQHXSdHWCco6EEY8ZwlW1coY9H6K3twIShGfN0t8DNpqq00FgwmVHrF1D5-MXXcYAm5PozAj8S3DTGOEFzWplgs4TAnEJglhCYxxBk2od_XTqR_n45-wM51LAV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2100330585</pqid></control><display><type>article</type><title>Catalytic antibodies in patients with systemic lupus erythematosus</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Pradhan, Vandana ; Pandit, Pallavi ; Surve, Prathamesh ; Lecerf, Maxime ; Rajadhyaksha, Anjali ; Nadkar, Milind ; Khadilkar, Prasad V ; Chougule, Durga A ; Naigaonkar, Aalaap A ; Lacroix-Desmazes, Sébastien ; Bayry, Jagadeesh ; Ghosh, Kanjaksha ; Kaveri, Srini V</creator><creatorcontrib>Pradhan, Vandana ; Pandit, Pallavi ; Surve, Prathamesh ; Lecerf, Maxime ; Rajadhyaksha, Anjali ; Nadkar, Milind ; Khadilkar, Prasad V ; Chougule, Durga A ; Naigaonkar, Aalaap A ; Lacroix-Desmazes, Sébastien ; Bayry, Jagadeesh ; Ghosh, Kanjaksha ; Kaveri, Srini V ; Centre de Recherche des Cordeliers, Equipe - Immunopathologie et Immunointervention Thérapeutique, Paris, France ; Department of Medicine, King Edward Memorial Hospital, Mumbai, India ; Department of Clinical & Experimental Immunology, National Institute of Immunohaematology, King Edward Memorial Hospital, Parel, Mumbai, India ; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris, France ; Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris, France ; Sorbonne Université, UMR S 1138, Paris, France</creatorcontrib><description>Antibodies with catalytic (hydrolytic) properties to DNA or RNA have been reported in systemic lupus erythematosus (SLE). However, it is well known that ethnicity plays an important role in the presentation of SLE and severity of the disease; hence, these data may not truly represent a general feature of all SLE patients. Therefore, we have analyzed the hydrolyzing activity of immunoglobulin G (IgG) of SLE patients from the Indian population with an aim to decode whether the catalytic antibody response represents part of an active disease process.
IgGs were isolated from the sera of 72 consecutive patients diagnosed with SLE. As a control, IgGs from healthy donors were used. The catalytic activity of IgG was measured by PFR-MCA and affinity-linked oligonucleotide nuclease assay.
IgGs from patients with SLE from the Indian subcontinent displayed significantly higher hydrolysis rates of both the surrogate substrate, PFR-MCA, and the DNA than IgG from healthy individuals. Intergroup comparisons of the IgG-PFR-MCA interactions with clinical manifestations of the disease demonstrated a significantly increased level of hydrolysis among the patients with renal involvement who tested positive for anti-dsDNA antibodies. The PFR-MCA hydrolysis also appears to be associated with the active disease (p=0.0988, vs. inactive group).
The prevalence of catalytic antibodies represents a general feature of SLE patients, irrespective of their origin.</description><identifier>ISSN: 2147-9720</identifier><identifier>EISSN: 2148-4279</identifier><identifier>DOI: 10.5152/eurjrheum.2018.17194</identifier><identifier>PMID: 30185370</identifier><language>eng</language><publisher>Turkey: AVES</publisher><subject>Analysis ; Care and treatment ; Catalytic antibodies ; Development and progression ; Genetic aspects ; Health aspects ; Immunoglobulin G ; Immunology ; Life Sciences ; Original ; Systemic lupus erythematosus</subject><ispartof>European journal of rheumatology, 2018-09, Vol.5 (3), p.173-178</ispartof><rights>COPYRIGHT 2018 AVES</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>Copyright by 2018 Medical Research and Education Association 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-2cc608bee6a2c818c4141dbad2d8c7891b7da6c7a5fe924a645686b3660a8dde3</citedby><orcidid>0000-0001-8161-6701 ; 0000-0002-6146-9545 ; 0000-0003-1790-6127 ; 0000-0001-9990-8059 ; 0000-0002-5913-3778 ; 0000-0003-0498-9808 ; 0000-0002-1477-2162 ; 0000-0001-6106-1286 ; 0000-0002-0837-4053 ; 0000-0002-0645-6565 ; 0000-0001-5625-8447 ; 0000-0002-1976-6108 ; 0000-0003-2717-3123</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116854/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116854/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30185370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02328224$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Pradhan, Vandana</creatorcontrib><creatorcontrib>Pandit, Pallavi</creatorcontrib><creatorcontrib>Surve, Prathamesh</creatorcontrib><creatorcontrib>Lecerf, Maxime</creatorcontrib><creatorcontrib>Rajadhyaksha, Anjali</creatorcontrib><creatorcontrib>Nadkar, Milind</creatorcontrib><creatorcontrib>Khadilkar, Prasad V</creatorcontrib><creatorcontrib>Chougule, Durga A</creatorcontrib><creatorcontrib>Naigaonkar, Aalaap A</creatorcontrib><creatorcontrib>Lacroix-Desmazes, Sébastien</creatorcontrib><creatorcontrib>Bayry, Jagadeesh</creatorcontrib><creatorcontrib>Ghosh, Kanjaksha</creatorcontrib><creatorcontrib>Kaveri, Srini V</creatorcontrib><creatorcontrib>Centre de Recherche des Cordeliers, Equipe - Immunopathologie et Immunointervention Thérapeutique, Paris, France</creatorcontrib><creatorcontrib>Department of Medicine, King Edward Memorial Hospital, Mumbai, India</creatorcontrib><creatorcontrib>Department of Clinical & Experimental Immunology, National Institute of Immunohaematology, King Edward Memorial Hospital, Parel, Mumbai, India</creatorcontrib><creatorcontrib>Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris, France</creatorcontrib><creatorcontrib>Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris, France</creatorcontrib><creatorcontrib>Sorbonne Université, UMR S 1138, Paris, France</creatorcontrib><title>Catalytic antibodies in patients with systemic lupus erythematosus</title><title>European journal of rheumatology</title><addtitle>Eur J Rheumatol</addtitle><description>Antibodies with catalytic (hydrolytic) properties to DNA or RNA have been reported in systemic lupus erythematosus (SLE). However, it is well known that ethnicity plays an important role in the presentation of SLE and severity of the disease; hence, these data may not truly represent a general feature of all SLE patients. Therefore, we have analyzed the hydrolyzing activity of immunoglobulin G (IgG) of SLE patients from the Indian population with an aim to decode whether the catalytic antibody response represents part of an active disease process.
IgGs were isolated from the sera of 72 consecutive patients diagnosed with SLE. As a control, IgGs from healthy donors were used. The catalytic activity of IgG was measured by PFR-MCA and affinity-linked oligonucleotide nuclease assay.
IgGs from patients with SLE from the Indian subcontinent displayed significantly higher hydrolysis rates of both the surrogate substrate, PFR-MCA, and the DNA than IgG from healthy individuals. Intergroup comparisons of the IgG-PFR-MCA interactions with clinical manifestations of the disease demonstrated a significantly increased level of hydrolysis among the patients with renal involvement who tested positive for anti-dsDNA antibodies. The PFR-MCA hydrolysis also appears to be associated with the active disease (p=0.0988, vs. inactive group).
The prevalence of catalytic antibodies represents a general feature of SLE patients, irrespective of their origin.</description><subject>Analysis</subject><subject>Care and treatment</subject><subject>Catalytic antibodies</subject><subject>Development and progression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Immunoglobulin G</subject><subject>Immunology</subject><subject>Life Sciences</subject><subject>Original</subject><subject>Systemic lupus erythematosus</subject><issn>2147-9720</issn><issn>2148-4279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNptUl1rFDEUDaLYsvYfiAz4og-zzdfk40VYF7XCQl_qc8gkdzop87FOMi37781062Kl5CHh3nPOvZwchN4TvK5IRS9hnu6mFuZ-TTFRayKJ5q_QOSVclZxK_frxLUstKT5DFzHeYYyJpFQT-RadsUyqmMTn6OvWJtsdUnCFHVKoRx8gFmEo9jYFGFIsHkJqi3iICfoM6ub9HAuYDqmF3qYxzvEdetPYLsLF071Cv75_u9lelbvrHz-3m13pmGappM4JrGoAYalTRDlOOPG19dQrJ5UmtfRWOGmrBjTlVvBKKFEzIbBV3gNboS9H3f1c9-Bd3m6yndlPobfTwYw2mOedIbTmdrw3ghChKp4FPh8F2v9oV5udWWqYMqoo5fckYz89DZvG3zPEZPoQHXSdHWCco6EEY8ZwlW1coY9H6K3twIShGfN0t8DNpqq00FgwmVHrF1D5-MXXcYAm5PozAj8S3DTGOEFzWplgs4TAnEJglhCYxxBk2od_XTqR_n45-wM51LAV</recordid><startdate>20180901</startdate><enddate>20180901</enddate><creator>Pradhan, Vandana</creator><creator>Pandit, Pallavi</creator><creator>Surve, Prathamesh</creator><creator>Lecerf, Maxime</creator><creator>Rajadhyaksha, Anjali</creator><creator>Nadkar, Milind</creator><creator>Khadilkar, Prasad V</creator><creator>Chougule, Durga A</creator><creator>Naigaonkar, Aalaap A</creator><creator>Lacroix-Desmazes, Sébastien</creator><creator>Bayry, Jagadeesh</creator><creator>Ghosh, Kanjaksha</creator><creator>Kaveri, Srini V</creator><general>AVES</general><general>Medical Research and Education Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8161-6701</orcidid><orcidid>https://orcid.org/0000-0002-6146-9545</orcidid><orcidid>https://orcid.org/0000-0003-1790-6127</orcidid><orcidid>https://orcid.org/0000-0001-9990-8059</orcidid><orcidid>https://orcid.org/0000-0002-5913-3778</orcidid><orcidid>https://orcid.org/0000-0003-0498-9808</orcidid><orcidid>https://orcid.org/0000-0002-1477-2162</orcidid><orcidid>https://orcid.org/0000-0001-6106-1286</orcidid><orcidid>https://orcid.org/0000-0002-0837-4053</orcidid><orcidid>https://orcid.org/0000-0002-0645-6565</orcidid><orcidid>https://orcid.org/0000-0001-5625-8447</orcidid><orcidid>https://orcid.org/0000-0002-1976-6108</orcidid><orcidid>https://orcid.org/0000-0003-2717-3123</orcidid></search><sort><creationdate>20180901</creationdate><title>Catalytic antibodies in patients with systemic lupus erythematosus</title><author>Pradhan, Vandana ; Pandit, Pallavi ; Surve, Prathamesh ; Lecerf, Maxime ; Rajadhyaksha, Anjali ; Nadkar, Milind ; Khadilkar, Prasad V ; Chougule, Durga A ; Naigaonkar, Aalaap A ; Lacroix-Desmazes, Sébastien ; Bayry, Jagadeesh ; Ghosh, Kanjaksha ; Kaveri, Srini V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-2cc608bee6a2c818c4141dbad2d8c7891b7da6c7a5fe924a645686b3660a8dde3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Analysis</topic><topic>Care and treatment</topic><topic>Catalytic antibodies</topic><topic>Development and progression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Immunoglobulin G</topic><topic>Immunology</topic><topic>Life Sciences</topic><topic>Original</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pradhan, Vandana</creatorcontrib><creatorcontrib>Pandit, Pallavi</creatorcontrib><creatorcontrib>Surve, Prathamesh</creatorcontrib><creatorcontrib>Lecerf, Maxime</creatorcontrib><creatorcontrib>Rajadhyaksha, Anjali</creatorcontrib><creatorcontrib>Nadkar, Milind</creatorcontrib><creatorcontrib>Khadilkar, Prasad V</creatorcontrib><creatorcontrib>Chougule, Durga A</creatorcontrib><creatorcontrib>Naigaonkar, Aalaap A</creatorcontrib><creatorcontrib>Lacroix-Desmazes, Sébastien</creatorcontrib><creatorcontrib>Bayry, Jagadeesh</creatorcontrib><creatorcontrib>Ghosh, Kanjaksha</creatorcontrib><creatorcontrib>Kaveri, Srini V</creatorcontrib><creatorcontrib>Centre de Recherche des Cordeliers, Equipe - Immunopathologie et Immunointervention Thérapeutique, Paris, France</creatorcontrib><creatorcontrib>Department of Medicine, King Edward Memorial Hospital, Mumbai, India</creatorcontrib><creatorcontrib>Department of Clinical & Experimental Immunology, National Institute of Immunohaematology, King Edward Memorial Hospital, Parel, Mumbai, India</creatorcontrib><creatorcontrib>Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris, France</creatorcontrib><creatorcontrib>Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris, France</creatorcontrib><creatorcontrib>Sorbonne Université, UMR S 1138, Paris, France</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pradhan, Vandana</au><au>Pandit, Pallavi</au><au>Surve, Prathamesh</au><au>Lecerf, Maxime</au><au>Rajadhyaksha, Anjali</au><au>Nadkar, Milind</au><au>Khadilkar, Prasad V</au><au>Chougule, Durga A</au><au>Naigaonkar, Aalaap A</au><au>Lacroix-Desmazes, Sébastien</au><au>Bayry, Jagadeesh</au><au>Ghosh, Kanjaksha</au><au>Kaveri, Srini V</au><aucorp>Centre de Recherche des Cordeliers, Equipe - Immunopathologie et Immunointervention Thérapeutique, Paris, France</aucorp><aucorp>Department of Medicine, King Edward Memorial Hospital, Mumbai, India</aucorp><aucorp>Department of Clinical & Experimental Immunology, National Institute of Immunohaematology, King Edward Memorial Hospital, Parel, Mumbai, India</aucorp><aucorp>Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris, France</aucorp><aucorp>Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris, France</aucorp><aucorp>Sorbonne Université, UMR S 1138, Paris, France</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Catalytic antibodies in patients with systemic lupus erythematosus</atitle><jtitle>European journal of rheumatology</jtitle><addtitle>Eur J Rheumatol</addtitle><date>2018-09-01</date><risdate>2018</risdate><volume>5</volume><issue>3</issue><spage>173</spage><epage>178</epage><pages>173-178</pages><issn>2147-9720</issn><eissn>2148-4279</eissn><abstract>Antibodies with catalytic (hydrolytic) properties to DNA or RNA have been reported in systemic lupus erythematosus (SLE). However, it is well known that ethnicity plays an important role in the presentation of SLE and severity of the disease; hence, these data may not truly represent a general feature of all SLE patients. Therefore, we have analyzed the hydrolyzing activity of immunoglobulin G (IgG) of SLE patients from the Indian population with an aim to decode whether the catalytic antibody response represents part of an active disease process.
IgGs were isolated from the sera of 72 consecutive patients diagnosed with SLE. As a control, IgGs from healthy donors were used. The catalytic activity of IgG was measured by PFR-MCA and affinity-linked oligonucleotide nuclease assay.
IgGs from patients with SLE from the Indian subcontinent displayed significantly higher hydrolysis rates of both the surrogate substrate, PFR-MCA, and the DNA than IgG from healthy individuals. Intergroup comparisons of the IgG-PFR-MCA interactions with clinical manifestations of the disease demonstrated a significantly increased level of hydrolysis among the patients with renal involvement who tested positive for anti-dsDNA antibodies. The PFR-MCA hydrolysis also appears to be associated with the active disease (p=0.0988, vs. inactive group).
The prevalence of catalytic antibodies represents a general feature of SLE patients, irrespective of their origin.</abstract><cop>Turkey</cop><pub>AVES</pub><pmid>30185370</pmid><doi>10.5152/eurjrheum.2018.17194</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-8161-6701</orcidid><orcidid>https://orcid.org/0000-0002-6146-9545</orcidid><orcidid>https://orcid.org/0000-0003-1790-6127</orcidid><orcidid>https://orcid.org/0000-0001-9990-8059</orcidid><orcidid>https://orcid.org/0000-0002-5913-3778</orcidid><orcidid>https://orcid.org/0000-0003-0498-9808</orcidid><orcidid>https://orcid.org/0000-0002-1477-2162</orcidid><orcidid>https://orcid.org/0000-0001-6106-1286</orcidid><orcidid>https://orcid.org/0000-0002-0837-4053</orcidid><orcidid>https://orcid.org/0000-0002-0645-6565</orcidid><orcidid>https://orcid.org/0000-0001-5625-8447</orcidid><orcidid>https://orcid.org/0000-0002-1976-6108</orcidid><orcidid>https://orcid.org/0000-0003-2717-3123</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2147-9720 |
ispartof | European journal of rheumatology, 2018-09, Vol.5 (3), p.173-178 |
issn | 2147-9720 2148-4279 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6116854 |
source | DOAJ Directory of Open Access Journals; PubMed Central; EZB Electronic Journals Library |
subjects | Analysis Care and treatment Catalytic antibodies Development and progression Genetic aspects Health aspects Immunoglobulin G Immunology Life Sciences Original Systemic lupus erythematosus |
title | Catalytic antibodies in patients with systemic lupus erythematosus |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A19%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Catalytic%20antibodies%20in%20patients%20with%20systemic%20lupus%20erythematosus&rft.jtitle=European%20journal%20of%20rheumatology&rft.au=Pradhan,%20Vandana&rft.aucorp=Centre%20de%20Recherche%20des%20Cordeliers,%20Equipe%20-%20Immunopathologie%20et%20Immunointervention%20Th%C3%A9rapeutique,%20Paris,%20France&rft.date=2018-09-01&rft.volume=5&rft.issue=3&rft.spage=173&rft.epage=178&rft.pages=173-178&rft.issn=2147-9720&rft.eissn=2148-4279&rft_id=info:doi/10.5152/eurjrheum.2018.17194&rft_dat=%3Cgale_pubme%3EA559690637%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2100330585&rft_id=info:pmid/30185370&rft_galeid=A559690637&rfr_iscdi=true |